BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu M, Li S, Zhang Q, Xu Z, Wang J, Sun H. Oral engineered Bifidobacterium longum expressing rhMnSOD to suppress experimental colitis. Int Immunopharmacol. 2018;57:25-32. [PMID: 29455070 DOI: 10.1016/j.intimp.2018.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Rahamim V, Azagury A. Bioengineered Biomimetic and Bioinspired Noninvasive Drug Delivery Systems. Adv Funct Mater 2021;31:2102033. [DOI: 10.1002/adfm.202102033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ye J, Erland LAE, Gill SK, Bishop SL, Verdugo-Meza A, Murch SJ, Gibson DL. Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products. Biomolecules 2021;11:738. [PMID: 34063522 DOI: 10.3390/biom11050738] [Reference Citation Analysis]
3 Kang M, Choe D, Kim K, Cho BK, Cho S. Synthetic Biology Approaches in The Development of Engineered Therapeutic Microbes. Int J Mol Sci. 2020;21:8744. [PMID: 33228099 DOI: 10.3390/ijms21228744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
4 Zuo F, Chen S, Marcotte H. Engineer probiotic bifidobacteria for food and biomedical applications - Current status and future prospective. Biotechnology Advances 2020;45:107654. [DOI: 10.1016/j.biotechadv.2020.107654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
5 Ruiz L, Esteban-Torres M, van Sinderen D. A Resource for Cloning and Expression Vectors Designed for Bifidobacteria: Overview of Available Tools and Biotechnological Applications. Methods Mol Biol 2021;2278:157-82. [PMID: 33649956 DOI: 10.1007/978-1-0716-1274-3_14] [Reference Citation Analysis]
6 Aggarwal N, Breedon AME, Davis CM, Hwang IY, Chang MW. Engineering probiotics for therapeutic applications: recent examples and translational outlook. Current Opinion in Biotechnology 2020;65:171-9. [DOI: 10.1016/j.copbio.2020.02.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
7 Mijan MA, Lim BO. Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends. World J Gastroenterol 2018; 24(25): 2673-2685 [PMID: 29991873 DOI: 10.3748/wjg.v24.i25.2673] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 49] [Article Influence: 14.8] [Reference Citation Analysis]
8 Pesce M, Seguella L, Del Re A, Lu J, Palenca I, Corpetti C, Rurgo S, Sanseverino W, Sarnelli G, Esposito G. Next-Generation Probiotics for Inflammatory Bowel Disease. Int J Mol Sci 2022;23:5466. [PMID: 35628274 DOI: 10.3390/ijms23105466] [Reference Citation Analysis]
9 Dosoky NS, May-Zhang LS, Davies SS. Engineering the gut microbiota to treat chronic diseases. Appl Microbiol Biotechnol 2020;104:7657-71. [PMID: 32696297 DOI: 10.1007/s00253-020-10771-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
10 Breyner NM, Vilas Boas PB, Fernandes G, de Carvalho RD, Rochat T, Michel ML, Chain F, Sokol H, de Azevedo M, Myioshi A, Azevedo VA, Langella P, Bermúdez-Humarán LG, Chatel JM. Oral delivery of pancreatitis-associated protein by Lactococcus lactis displays protective effects in dinitro-benzenesulfonic-acid-induced colitis model and is able to modulate the composition of the microbiota. Environ Microbiol 2019;21:4020-31. [PMID: 31325218 DOI: 10.1111/1462-2920.14748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Xiong T, Zheng X, Zhang K, Wu H, Dong Y, Zhou F, Cheng B, Li L, Xu W, Su J, Huang J, Jiang Z, Li B, Zhang B, Lv G, Chen S. Ganluyin ameliorates DSS-induced ulcerative colitis by inhibiting the enteric-origin LPS/TLR4/NF-κB pathway. J Ethnopharmacol 2022;289:115001. [PMID: 35085745 DOI: 10.1016/j.jep.2022.115001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Effendi SSW, Ng IS. Prospective and challenges of live bacterial therapeutics from a superhero Escherichia coli Nissle 1917. Crit Rev Microbiol 2022;:1-17. [PMID: 35947523 DOI: 10.1080/1040841X.2022.2109405] [Reference Citation Analysis]
13 Fei Z, Li S, Wang J, Wang Y, Jiang Z, Huang W, Sun H. Rhodotorula glutinis as a living cell liposome to deliver polypeptide drugs in vivo. Drug Deliv 2019;26:51-62. [PMID: 30744426 DOI: 10.1080/10717544.2018.1551439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Shen H, Zhao Z, Zhao Z, Chen Y, Zhang L. Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases. Int J Mol Sci 2022;23:594. [PMID: 35054790 DOI: 10.3390/ijms23020594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
15 Shen Y, Zou J, Chen M, Zhang Z, Liu C, Jiang S, Qian D, Duan JA. Protective effects of Lizhong decoction on ulcerative colitis in mice by suppressing inflammation and ameliorating gut barrier. J Ethnopharmacol 2020;259:112919. [PMID: 32360800 DOI: 10.1016/j.jep.2020.112919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
16 Shamoon M, Martin NM, O'Brien CL. Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications. Pharmacol Res. 2019;148:104344. [PMID: 31400403 DOI: 10.1016/j.phrs.2019.104344] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
17 Bellocchi C, Volkmann ER. Update on the Gastrointestinal Microbiome in Systemic Sclerosis. Curr Rheumatol Rep 2018;20:49. [PMID: 29943234 DOI: 10.1007/s11926-018-0758-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
18 Barra M, Danino T, Garrido D. Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases. Front Bioeng Biotechnol 2020;8:265. [PMID: 32296696 DOI: 10.3389/fbioe.2020.00265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
19 Inda ME, Broset E, Lu TK, de la Fuente-Nunez C. Emerging Frontiers in Microbiome Engineering. Trends Immunol 2019;40:952-73. [PMID: 31601521 DOI: 10.1016/j.it.2019.08.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]